BECLOMETASONE EXTRA-FINE/ FORMOTEROL (Luforbec pMDI®)
Clinical Indication
Asthma and COPD
Comments
1st choice aerosol
Management of Asthma in Adults
LLR Adult Asthma Guideline (≥18 years) AIR and MART FAQ
The LLR COPD guidelines have been updated (June 2026) and ICS/LABA combinations are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines.
Date of classification
July 2024
Green
Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.